Novo Nordisk GLP-1 Drug Alzheimer's Trials Fail
Favicon 
www.newsmax.com

Novo Nordisk GLP-1 Drug Alzheimer's Trials Fail

Novo Nordisk's closely-watched Alzheimer's trials of an older oral version of its semaglutide drug failed to help slow the progression of the brain-wasting disease, the firm said on Monday, a blow to the obesity drug giant that sent its shares sliding. The trials, which Novo...